// App-Quantinova.ai

: PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Researchers

Presenter

  • Lauren Christine Harshman

Principal Investigators

  • Mohamad E. Allaf

  • David F. McDermott

  • Charles G. Drake

  • Sabina Signoretti

  • David Cella

  • Rajan T. Gupta

  • Brian M. Shuch

  • Primo Lara

  • Anil Kapoor

  • Daniel Yick Chin Heng

  • Bradley Leibovich

  • M. Dror Michaelson

  • Toni K. Choueiri

  • Viraj A. Master

  • Michael A.S. Jewett

  • Deb Maskens

  • Naomi B. Haas

  • Michael Anthony Carducci

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD

  • Beth Israel Deaconess Medical Center/ Dana-Farber Cancer Institute, Boston, MA

  • Herbert Irving Comprehensive Cancer Center, New York, NY

  • Brigham and Women's Hospital, Brookline, MA

  • Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  • Duke University Medical Center, Durham, NC

  • University of California, Los Angeles, Los Angeles, CA

  • University of California, San Francisco, CA

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • University of Calgary, Calgary, AB, Canada

  • Mayo Clinic, Rochester, MN

  • Massachusetts General Hospital, Boston, MA

  • Dana-Farber Cancer Institute/Brigham and Women’s Hospital and Harvard University School of Medicine, Boston, MA

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • IKCC, Guelph, ON, Canada

  • Penn Medicine Abramson Cancer Center, Philadelphia, PA

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine,, Baltimore, MD

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A


Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03055013

Sponsors

  • N/A

Result

  • N/A